Content deleted Content added
added 2024 global 2000 ranking with citation |
moved 10K ref out of infobox and added pages for instances; noted one web citation is a registration-needed site |
||
Line 10:
| predecessor =
| founded = {{Start date and age|2012|04|10}}
| location = [[North Chicago, Illinois]], United States
| area_served = 170+ countries worldwide
| key_people = {{ubl|Richard A. Gonzalez ([[chairman]] and [[Chief executive officer|CEO]])|Robert Michael ([[President (corporate title)|president]] and [[Chief operating officer|COO]])}}
Line 34:
| divisions =
| website = {{URL|abbvie.com}}
}}
'''AbbVie Inc.''' is an American [[pharmaceutical]] company headquartered in [[North Chicago, Illinois]]. It is ranked sixth on the [[list of largest biomedical companies by revenue]]. In 2023, the company's seat in [[Forbes Global 2000]] was 74,<ref>{{Cite web |date=8 June 2023 |editor-last=Murphy |editor-first=Andrea |editor2-last=Tucker |editor2-first=Hank |title=The Global 2000 2023 |url=https://www.forbes.com/lists/global2000/?sh=51d599675ac0 |archive-url=https://web.archive.org/web/20240226095032/https://www.forbes.com/lists/global2000/?sh=7cf2e0855ac0 |archive-date=2024-02-26 |access-date=2024-02-07 |website=Forbes |page=2<!--via page links --> |lang=en}}</ref> and rank 89 on the 2024 list.<ref>{{Cite web |date=6 June 2024 |editor-last=Murphy |editor-first=Andrea |editor2-last=Schifrin |editor2-first=Matt |title=The Global 2000 |url=https://www.forbes.com/lists/global2000/?sh=51d599675ac0 |archive-url=https://web.archive.org/web/20240129031905/https://www.forbes.com/lists/global2000/?sh=230a69b65ac0 |archive-date=29 Jan 2024 |access-date=29 August 2024 |publisher=Forbes |page=2<!-- based on pagination links at bottom of page -->}}</ref> The company's primary product is [[Humira]] (adalimumab) ($14{{nbsp}}billion in 2023 revenues, 27{{nbsp}}percent of total), administered via injection. It is approved to treat [[autoimmune disease]]s including [[rheumatoid arthritis]], [[Crohn's disease]], [[plaque psoriasis]], and [[ulcerative colitis]].
It developed [[Skyrizi]] ($7.8{{nbsp}}billion in 2023 revenues), an [[interleukin-23]] (IL-23) inhibitor also used to treat autoimmune diseases. Its other major products include [[Botox]] ($5.7{{nbsp}}billion in 2023 revenues), [[Imbruvica]] to treat [[cancer]] ($3.6{{nbsp}}billion in 2023 revenues), [[Rinvoq]] to treat [[arthritis]] ($4{{nbsp}}billion in 2023 revenues), [[Venclexta]] to treat [[leukemia]] and [[lymphoma]] ($2.3{{nbsp}}billion in 2023 revenues), [[Vraylar]] to treat [[schizophrenia]] and [[bipolar disorder]] ($2.7{{nbsp}}billion in 2023 revenues), and [[Mavyret]] to treat [[Hepatitis C]] ($1.4{{nbsp}}billion in 2023 revenues).<ref name=10K/> The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and [[cystic fibrosis]].<ref name=10K/><ref>{{cite web |url=https://endpts.com/abbvie-doubles-down-on-cystic-fibrosis-rd-adding-a-new-drug-to-the-pipeline-as-vertex-seals-its-domination-of-the-field-with-trikafta-ok/ |
In 2023, Humira began facing competition from a [[biosimilar]] developed by [[Amgen]]. The company is also developing a drug for [[Parkinson's disease]] that could be a [[blockbuster drug]] in 2027 and is awaiting approval from the [[Food and Drug Administration]] for epcoritamab, a blood-cancer therapy under development in partnership with [[Genmab]].<ref>{{Cite news | url=https://www.wsj.com/articles/abbvie-aims-for-new-drugs-to-boost-sales-as-competitors-target-humira-11675638126 | title=AbbVie Aims for New Drugs to Boost Sales as Competitors Target Humira | first=Jared S. | last=Hopkins | work=[[The Wall Street Journal]] | date=February 6, 2023 | url-access=subscription}}</ref>
| |||